Evidence map›Paper›PMID 37405215›Full record

ReviewCancer diagnosis & prognosis

Mutational Signatures in Salivary Gland Carcinomas.

Aristeidis Chrysovergis, Vasileios Papanikolaou, Despoina Spyropoulou, Dimitrios Roukas, Asimakis D Asimakopoulos, George Papanastasiou, Sofianiki Mastronikoli, Evangelos Falidas, Sotirios Papouliakos, Evangelos Tsiambas and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aristeidis ChrysovergisFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Vasileios PapanikolaouFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Despoina Spyropoulou *Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece.
Dimitrios Roukas *Department of Psychiatry, 417 Veterans Army Hospital (NIMTS), Athens, Greece.
Asimakis D Asimakopoulos *Department of Otorhinolaryngology, Centre Hospital, Sion, Switzerland.
George PapanastasiouDepartment of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
Sofianiki MastronikoliBrighton and Sussex Medical School, Brighton, U.K.
Evangelos FalidasDepartment of Surgery, Halkida General Hospital, Halkida, Greece.
Sotirios PapouliakosDepartment of Otolaryngology, Gennimatas GNA Hospital, Athens, Greece.
Evangelos TsiambasDepartment of Cytology, 417 Veterans Army Hospital (NIMTS), Athens, Greece.
Pavlos PantosFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Vasileios RagosDepartment of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
Dimitrios PeschosDepartment of Physiology, Medical School, University of Ioannina, Ioannina, Greece.
Nicholas MastronikolisDepartment of Otolaryngology, Medical School, University of Patras, Patras, Greece.
Efthymios KyrodimosFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salivary gland carcinomas belong to the head and neck carcinoma super category of malignancies. They are characterized by histopathological diversity and comprise a variety of entities and subtypes. Mucoepidermoid, adenoid cystic and salivary duct carcinomas represent the most prominent malignancies. Concerning their corresponding genetic background, a broad spectrum of gene and chromosomal imbalances has been detected. Point mutations and deletions, amplifications and translocations, combined or not with chromosomal aneuploidy/polysomy/monosomy, create a landscape of specific genetic signatures that affect the biological behavior of these tumors and modify response rates to potential targeted therapeutic strategies. In the current molecular review, we focused on the categorization and description of the most important mutational signatures in salivary gland carcinomas.

Indexed as

carcinomageneglandmutationreviewSalivary

Identifiers

PMID37405215
PMCPMC10316062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.